Quote this publication Share Print

QUTENZA (capsaicin), local analgesic patch

PAIN - Update
Opinions on drugs - Posted on Mar 29 2017

Reason for request

Re-assessment of the actual benefit and the improvement in actual benefit

No clinical benefit demonstrated in peripheral neuropathy pain


  • QUTENZA is a transdermal system with Marketing Authorisation in the treatment of peripheral neuropathic pain in adults, either alone or in combination with other analgesics.
  • Its efficacy is limited and its use is commonly associated with painful reactions at the application site.
  • QUTENZA is a second-line and beyond treatment, in combination with other analgesics, in the management of local, evaluable and delimited peripheral neuropathic pain in nondiabetic adults.
  • It should be prescribed after consultation with a pain specialist and its use must be re-evaluated regularly due to questions relative to its long-term use (maintenance of efficacy and absence of altered perception).


Clinical Benefit




Clinical Added Value

no clinical added value


Contact Us

Évaluation des médicaments